uniQure N.V. (QURE) shareholders
Close on Nov 18, 2026Market cap $1.41BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (9.87%) | 6,150,000 | 9.87% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (9.80%) | 6,059,574 | 9.80% | 13G (passive) | Sep 30, 2025 |
| JPMorgan Chase & Co. | 5,951,794 | 8.50% | 13G (passive) amendment | Sep 30, 2026 |
| JPMorgan Chase & Co | 4,866,211 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (8.90%) | 4,792,572 | 8.90% | 13G (passive) amendment | Mar 31, 2025 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (7.90%) | 4,265,428 | 7.90% | 13G (passive) | Mar 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong (5.70%) | 3,941,572 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (6.00%) | 3,711,462 | 6.00% | 13G (passive) amendment | Dec 31, 2025 |
| Aberdeen Group plc Joint filing with abrdn Inc. (5.91%) | 3,678,640 | 5.91% | 13G (passive) amendment | Dec 31, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (6.60%) | 3,625,000 | 6.60% | 13G (passive) | Jun 30, 2025 |
| SIG Brokerage, LP Joint filing with G1 Execution Services, LLC (5.70%), Susquehanna Portfolio Strategies, LLC (5.70%) and 1 more | 3,536,485 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (6.12%), Daniel Mack (6.12%) | 2,982,013 | 6.12% | 13G (passive) amendment | Sep 30, 2024 |
| Joe Lewis Joint filing with This Schedule 13G is jointly filed by Boxer Capital, LLC (“ Boxer Capital ”), Boxer Asset Management Inc. (“ Boxer Management ”) and Joe Lewis (collectively, the “ Reporting Persons ”). Boxer Manageme (5.10%), Boxer Asset Management Inc. (5.10%) | 2,500,000 | 5.10% | 13G (passive) | Jul 10, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of QURE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6,727,777 | 9.70% | $309.88M | +768,182 | 2.78% |
| JPMorgan Chase & Co | 4,867,755 | 7.02% | $230.81M | +2,030,289 | 0.01% |
| Rtw Investments, LP | 3,941,572 | 5.68% | $181.55M | +1,355,216 | 1.55% |
| State Street Corp | 2,903,825 | 4.19% | $133.75M | +643,313 | 0.00% |
| abrdn plc | 2,848,117 | 4.11% | $131.18M | −2,458,269 | 0.18% |
| BlackRock, Inc. | 1,877,453 | 2.71% | $86.48M | +143,995 | 0.00% |
| Orbimed Advisors LLC | 1,807,486 | 2.61% | $83.25M | −328,663 | 1.54% |
| Jane Street Group, LLC | 1,610,483 | 2.32% | $74.18M | +974,488 | 0.01% |
| Jennison Associates LLC | 1,561,412 | 2.25% | $71.92M | +327,623 | 0.04% |
| Boxer Capital Management, LLC | 1,503,300 | 2.17% | $69.24M | +841,300 | 5.21% |
| Goldman Sachs Group Inc | 1,475,956 | 2.13% | $67.98M | +212,720 | 0.01% |
| Two Sigma Investments, LP | 1,462,024 | 2.11% | $67.34M | −1,213,847 | 0.05% |
| Two Seas Capital LP | 1,441,410 | 2.08% | $66.39M | +141,410 | 1.31% |
| FMR LLC | 1,270,068 | 1.83% | $58.50M | −473,740 | 0.00% |
| Mak Capital One LLC | 1,232,051 | 1.78% | $56.75M | +790,846 | 7.95% |
| Mpm Bioimpact LLC | 1,225,855 | 1.77% | $56.46M | −143,376 | 3.44% |
| Morgan Stanley | 1,066,639 | 1.54% | $49.13M | +700,522 | 0.00% |
| Assenagon Asset Management S.A. | 1,027,060 | 1.48% | $47.31M | +880,311 | 0.03% |
| Vestal Point Capital, LP | 935,000 | 1.35% | $43.07M | +576,004 | 1.01% |
| Maverick Capital Ltd | 925,383 | 1.33% | $42.62M | +227,743 | 0.38% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 254 | 67M | 96.0% | 91 / 86 | 59 / 48 | 21M | 15M |
| Q1 2026 | 213 | 60M | 86.7% | 47 / 72 | 61 / 52 | 17M | 18M |
| Q4 2025 | 226 | 62M | 89.3% | 73 / 73 | 61 / 63 | 23M | 17M |
| Q3 2025 | 219 | 57M | 81.6% | 97 / 49 | 61 / 20 | 20M | 17M |
| Q2 2025 | 143 | 53M | 76.9% | 32 / 42 | 49 / 30 | 12M | 9M |
| Q1 2025 | 141 | 50M | 72.3% | 24 / 54 | 37 / 20 | 15M | 6M |
| Q4 2024 | 138 | 42M | 60.1% | 36 / 35 | 48 / 27 | 15M | 13M |
| Q3 2024 | 131 | 39M | 56.8% | 32 / 36 | 40 / 16 | 15M | 9M |
| Q2 2024 | 117 | 35M | 50.6% | 18 / 36 | 37 / 33 | 6M | 8M |
| Q1 2024 | 132 | 37M | 52.7% | 19 / 52 | 33 / 30 | 8M | 14M |
| Q4 2023 | 144 | 43M | 62.3% | 28 / 44 | 55 / 42 | 15M | 7M |
| Q3 2023 | 160 | 36M | 52.2% | 32 / 60 | 44 / 46 | 13M | 11M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew C. Kapusta | CEO, Managing Director | 531,109 | 0.77% | Jul 7, 2026 |
| Walid Abi-Saab | Chief Medical Officer | 166,985 | 0.24% | Nov 3, 2026 |
| Jeannette Potts | Chief Legal Officer | 133,246 | 0.19% | Jun 17, 2026 |
| Kylie O'Keefe | Chief Customer & Strat Officer | 108,864 | 0.16% | Jun 12, 2026 |
| Christian Klemt | Chief Financial Officer | 238,581 | 0.34% | Mar 6, 2026 |
| David D. Meek | Director | 30,667 | 0.04% | Nov 10, 2026 |
| Jack Kaye | Director | 43,056 | 0.06% | Jul 2, 2026 |
| Madhavan Balachandran | Director | 49,644 | 0.07% | Jun 22, 2026 |
| Leonard E. Post | Director | 35,494 | 0.05% | Jun 12, 2026 |
| Robert Gut | Director | 32,259 | 0.05% | Jun 12, 2026 |
| Jeremy P. Springhorn | Director | 43,251 | 0.06% | Jun 12, 2026 |
| Rachelle Suzanne Jacques | Director | 33,903 | 0.05% | Jun 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David D. Meek Director | Nov 6, 2026 | Sale(10b5-1 plan) | −9,080 | $21.25 | $192.95K | 30,667 |
| Walid Abi-Saab Chief Medical Officer | Oct 30, 2026 | Award | +18,750 | – | – | 166,985 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −9,200 | $44.43 | $408.76K | 531,109 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −4,282 | $45.43 | $194.53K | 526,827 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Sale(10b5-1 plan) | −7,600 | $45.89 | $348.76K | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jul 2, 2026 | Option exercise | +21,082 | $19.39 | $408.78K | 540,309 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −10,000 | $46.46 | $464.60K | 168,235 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −20,000 | $46.40 | $928.00K | 148,235 |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | Option exercise | +10,000 | $5.59 | $55.90K | 178,235 |
| Jack Kaye Director | Jun 30, 2026 | Option exercise | +17,060 | $20.18 | $344.27K | 43,056 |
| Jack Kaye Director | Jun 30, 2026 | Sale(10b5-1 plan) | −4,107 | $46.49 | $190.93K | 25,996 |
| Jack Kaye Director | Jun 30, 2026 | Option exercise | +4,107 | $37.00 | $151.96K | 30,103 |
| Jack Kaye Director | Jun 30, 2026 | Sale(10b5-1 plan) | −17,060 | $46.43 | $792.10K | 25,996 |
| Walid Abi-Saab Chief Medical Officer | Jun 26, 2026 | Sale | −1,434 | $46.86 | $67.20K | 168,235 |
| Matthew C. Kapusta CEO, Managing Director | Jun 25, 2026 | Sale(10b5-1 plan) | −28,716 | $50.02 | $1.44M | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jun 25, 2026 | Option exercise | +28,716 | $31.71 | $910.58K | 547,943 |
| Matthew C. Kapusta CEO, Managing Director | Jun 24, 2026 | Option exercise | +4,128 | $31.71 | $130.90K | 525,923 |
| Matthew C. Kapusta CEO, Managing Director | Jun 24, 2026 | Sale(10b5-1 plan) | −6,696 | $50.00 | $334.80K | 519,227 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Option exercise | +4,656 | $31.71 | $147.64K | 563,466 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Sale(10b5-1 plan) | −4,656 | $50.00 | $232.80K | 558,810 |
| Matthew C. Kapusta CEO, Managing Director | Jun 18, 2026 | Sale(10b5-1 plan) | −37,015 | $50.00 | $1.85M | 521,795 |
| Jack Kaye Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,295 | $42.57 | $225.41K | 25,996 |
| Jack Kaye Director | Jun 17, 2026 | Option exercise | +5,295 | $31.71 | $167.90K | 31,291 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −56,929 | $43.43 | $2.47M | 603,729 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −6,023 | $43.70 | $263.21K | 693,239 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −23,977 | $42.61 | $1.02M | 699,262 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Option exercise | +62,581 | $19.39 | $1.21M | 723,239 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −33,334 | $45.01 | $1.50M | 570,395 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −11,585 | $48.65 | $563.61K | 558,810 |
| Matthew C. Kapusta CEO, Managing Director | Jun 17, 2026 | Sale(10b5-1 plan) | −32,581 | $45.02 | $1.47M | 660,658 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −5,295 | $47.08 | $249.29K | 49,644 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −4,700 | $43.66 | $205.20K | 44,944 |
| Madhavan Balachandran Director | Jun 17, 2026 | Sale(10b5-1 plan) | −1,690 | $42.60 | $71.99K | 43,254 |
| Madhavan Balachandran Director | Jun 17, 2026 | Option exercise | +6,390 | $19.39 | $123.90K | 54,939 |
| Madhavan Balachandran Director | Jun 17, 2026 | Option exercise | +5,295 | $31.71 | $167.90K | 48,549 |
| Madhavan Balachandran Director | Jun 15, 2026 | Option exercise | +10,000 | $8.49 | $84.90K | 53,254 |
| Madhavan Balachandran Director | Jun 15, 2026 | Sale(10b5-1 plan) | −10,000 | $27.85 | $278.50K | 43,254 |
| Jeannette Potts Chief Legal Officer | Jun 15, 2026 | Sale | −5,237 | $27.67 | $144.91K | 133,246 |
| Jeremy P. Springhorn Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 43,251 |
| Jack Kaye Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 25,996 |
| Madhavan Balachandran Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 43,254 |
| Kylie O'Keefe Chief Customer & Strat Officer | Jun 11, 2026 | Sale | −15,936 | $27.06 | $431.23K | 108,864 |
| Leonard E. Post Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 35,494 |
| Rachelle Suzanne Jacques Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 33,903 |
| David D. Meek Director | Jun 11, 2026 | Sale | −1,993 | $27.06 | $53.93K | 39,747 |
| Robert Gut Director | Jun 11, 2026 | Sale(10b5-1 plan) | −2,726 | $27.06 | $73.77K | 32,259 |
| Jeremy P. Springhorn Director | Jun 10, 2026 | Award | +7,550 | – | – | 45,244 |
| Jack Kaye Director | Jun 10, 2026 | Award | +7,550 | – | – | 27,989 |
| Madhavan Balachandran Director | Jun 10, 2026 | Award | +7,550 | – | – | 45,247 |
| Leonard E. Post Director | Jun 10, 2026 | Award | +7,550 | – | – | 37,487 |
| Rachelle Suzanne Jacques Director | Jun 10, 2026 | Award | +7,550 | – | – | 35,896 |
| David D. Meek Director | Jun 10, 2026 | Award | +7,550 | – | – | 41,740 |
| Robert Gut Director | Jun 10, 2026 | Award | +7,550 | – | – | 34,985 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −1,780 | $26.05 | $46.37K | 27,435 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −3,127 | $26.03 | $81.40K | 29,215 |
| Robert Gut Director | Jun 10, 2026 | Sale(10b5-1 plan) | −2,645 | $26.07 | $68.96K | 32,342 |
| Robert Gut Director | Jun 10, 2026 | Option exercise | +2,645 | $16.04 | $42.43K | 34,987 |
| Jack Kaye Director | Jun 3, 2026 | Option exercise | +2,645 | $16.04 | $42.43K | 23,084 |
| Jack Kaye Director | Jun 3, 2026 | Sale(10b5-1 plan) | −2,645 | $30.01 | $79.38K | 20,439 |
| Walid Abi-Saab Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −20,000 | $25.00 | $500.00K | 169,669 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of uniQure's stock actually held short. Settlement fails (shares not delivered on time) peaked at 52,675 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David D. Meek Director | Nov 6, 2026 | 9,080 | $192.95K | Nov 6, 2026 | Vested shares |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jul 2, 2026 | 21,082 | $951.93K | Jul 2, 2026 | Stock option exercise and sale |
| Jack Kaye Director | Jun 30, 2026 | 21,167 | $983.03K | Jun 30, 2026 | Stock option exercise pursuant to 10b51 plan |
| Walid Abi-Saab Chief Medical Officer | Jun 30, 2026 | 30,000 | $1.39M | Jun 30, 2026 | Stock option exercise pursuant to 10b51 plan |
| Walid Abi-Saab Chief Medical Officer | Jun 26, 2026 | 1,434 | $67.20K | Jun 26, 2026 | Restricted Stock Units Vesting |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 25, 2026 | 28,716 | $1.44M | Jun 25, 2026 | Stock option exercise and sale |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 24, 2026 | 6,696 | $334.80K | Jun 24, 2026 | Vested Stock from PSU and RSU |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 18, 2026 | 41,671 | $1.93M | Jun 18, 2026 | Vested Stock from PSU and RSU |
| Matthew C. Kapusta Officer, Director, CEO AND MANAGING DIRECTOR | Jun 17, 2026 | 164,429 | $7.07M | Jun 17, 2026 | Vested Stock from PSU and RSU pursuant to 10b51 plan |
| Jack Kaye Director | Jun 17, 2026 | 5,295 | $225.39K | Jun 17, 2026 | Stock option exercise pursuant to 10b51 plan |
| Madhavan Balachandran Director | Jun 17, 2026 | 11,685 | $526.46K | Jun 17, 2026 | Stock option exercise and sale Pursuant to 10b5-1 plan |
| Jeannette Potts Officer, CHIEF LEGAL OFFICER | Jun 15, 2026 | 5,237 | $144.89K | Jun 15, 2026 | RESTRICTED STOCK UNITS VESTING |
| Jack Kaye Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock units vesting |
| David D. Meek Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock unit vesting |
| Leonard E. Post Director | Jun 11, 2026 | 1,993 | $53.94K | Jun 11, 2026 | Restricted stock unit vesting |
See a number that looks wrong?